Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

Pediatric Blood & Cancer
Richard LockMalcolm A Smith


ABT-263 is a potent (K(i) < 1 nM) small-molecule BH3 mimetic that inhibits the antiapoptotic proteins Bcl-2, Bcl-x(L) and Bcl-w. The structurally related Bcl-2 inhibitor ABT-737 exhibits single-agent preclinical activity against lymphoma, small-cell lung carcinoma, and chronic lymphocytic leukemia and displays synergistic cytotoxicity with chemotherapeutics and radiation. ABT-263 was tested at concentrations ranging from 1.0 nM to 10.0 microM using 23 cell lines from the PPTP in vitro panel and was tested in 44 xenograft models representing nine distinct histologies using daily gavage administration of ABT-263 (100 mg/kg) or vehicle for 21 days. ABT-263 was active against approximately one-half of the cell lines of the PPTP in vitro panel. The median IC(50) for all of the lines in the panel was 1.91 microM. ABT-263 induced significant prolongation of the EFS distribution in 9 of 35 (26%) of the solid tumor xenografts, and in 5 of 6 (83%) of the evaluable ALL xenografts. ABT-263 induced no objective responses in the solid tumor panels, but induced CRs in 3 of 6 evaluable xenografts in the ALL panel, including two that were maintained for an additional 3 weeks following treatment cessation. ABT-263 demonstrated in vitro activity ...Continue Reading


Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Jul 1, 2004·Molecular and Cellular Biology·Ryoko KuribaraToshiya Inaba
Nov 3, 2004·The Journal of Experimental Medicine·Paula M OliverPhilippa Marrack
May 20, 2005·Nature·Tilman OltersdorfS H Rosenberg
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer K PetersonPeter J Houghton
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claire GrahamPeter J Houghton
Jun 10, 2006·Seminars in Cancer Biology·JeanMarie HoughtonTimothy C Wang
Jun 17, 2006·Cancer Research·A McGarry HoughtonSteven D Shapiro
Sep 6, 2006·British Journal of Cancer·R T KurmashevaPeter J Houghton
Oct 27, 2006·Pediatric Blood & Cancer·Peter J HoughtonMalcolm A Smith
Jan 4, 2007·The Journal of Clinical Investigation·Victoria Del Gaizo MooreAnthony Letai
Jan 6, 2007·Cell Death and Differentiation·H ZhangC Tse
Feb 27, 2007·Oncogene·J M Adams, S Cory


Jan 26, 2010·Cancer Chemotherapy and Pharmacology·S AcklerAlexander R Shoemaker
Jan 9, 2009·Apoptosis : an International Journal on Programmed Cell Death·S Fulda
Apr 29, 2010·Current Hematologic Malignancy Reports·Malcolm A Smith
Apr 4, 2009·Nature Reviews. Cancer·Mark S CraggClare L Scott
Dec 2, 2008·Nature Reviews. Drug Discovery·Guillaume LessenePeter M Colman
Nov 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kylie D MasonAndrew W Roberts
Jun 8, 2011·Antioxidants & Redox Signaling·S Fulda, Guido Kroemer
Sep 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin D ZeitlinJacques E Nör
Apr 1, 2009·Future Medicinal Chemistry·Giovanna Zinzalla, David E Thurston
Sep 8, 2012·Cellular and Molecular Life Sciences : CMLS·Giovanni MonacoGeert Bultynck
Jun 27, 2009·Leukemia & Lymphoma·Seong Lin KhawAndrew W Roberts
May 26, 2015·Expert Review of Anticancer Therapy·Xavier Thomas
Feb 19, 2015·International Journal of Molecular Sciences·Justus LieberJörg Fuchs
Nov 19, 2010·Expert Review of Hematology·Jean-Pierre Bourquin, Beat Bornhauser
Dec 1, 2009·Expert Opinion on Drug Discovery·Beverly A Teicher
Feb 11, 2014·Critical Reviews in Oncology/hematology·Khurum H KhanL Rhoda Molife
Nov 3, 2010·Cancer Letters·S Fulda
Mar 13, 2010·Cancer Treatment Reviews·Marco Wachtel, Beat W Schäfer
Aug 12, 2008·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ramona RodilaTawakol A El-Shourbagy
Oct 31, 2015·Pharmacology Research & Perspectives·S AcklerJonathan Hickson
Jan 17, 2009·Pediatric Blood & Cancer·S Fulda
Sep 4, 2008·Journal of Cellular Physiology·Asfar S Azmi, Ramzi M Mohammad
Sep 4, 2010·British Journal of Haematology·Alisa B Lee-SherickDouglas K Graham
Aug 4, 2010·Pediatric Blood & Cancer·Justus LieberSorin Armeanu-Ebinger
Mar 10, 2010·Environmental and Molecular Mutagenesis·David M Hockenbery
Nov 22, 2015·Journal of Hematology & Oncology·Shundong CangDelong Liu
Feb 7, 2012·Pediatric Hematology and Oncology·Jenny PotratzUta Dirksen
Apr 29, 2015·Mutation Research·Tanmay M ShekharChristine J Hawkins
Jan 22, 2013·Communicative & Integrative Biology·Qiang Liu, Hong-Gang Wang
Mar 1, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fieke LamersJan J Molenaar
Dec 14, 2011·International Journal of Biological Macromolecules·Pawan Kumar RaghavGurudutta U Gangenahalli
Mar 12, 2009·Journal of Cellular Biochemistry·Lars M Wagner, Mary K Danks
May 15, 2010·Nature Reviews. Drug Discovery·S FuldaGuido Kroemer
Dec 4, 2017·Critical Care Nurse·Cecilia St George-HyslopLinda G Fazari
Oct 28, 2019·Cancers·Zhang'e ChooZhi Xiong Chen
Dec 22, 2017·Expert Review of Hematology·Meera Yogarajah, Richard M Stone
Jul 19, 2017·The Journal of Biological Chemistry·Lauren M BrownPaul G Ekert
Apr 12, 2019·Frontiers in Oncology·Amanda McBrideNeil Palmisiano
Sep 2, 2016·Science Translational Medicine·Jessica LeonardBill H Chang
May 27, 2020·British Journal of Haematology·Paraskevi DiamantiAllison Blair
Jun 27, 2020·Blood·Stephen P Hunger, Elizabeth A Raetz
Jul 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Santi SuryaniRichard Lock
Feb 5, 2015·Cancer Research·Sarah E AlfordTimothy C Chambers
Jan 1, 2021·Frontiers in Pharmacology·Nur Najmi Mohamad AnuarAzizah Ugusman

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.